Cognitive function is an important end point of treatments in dementia clinical trials. Measuring cognitive function by standardized tests, however, is biased toward highly constrained environments (such as hospitals) in selected samples. Patient-powered real-world evidence using information and communication technology devices, including environmental and wearable sensors, may help to overcome these limitations. This position paper describes current and novel information and communication technology devices and algorithms to monitor behavior and function in people with prodromal and manifest stages of dementia continuously, and discusses clinical, technological, ethical, regulatory, and user-centered requirements for collecting real-world ...
Background: Functional decline in Alzheimer’s disease (AD) is typically measured using single-time p...
People living with cognitive impairment and dementia require regular screening of their symptomatolo...
Background Functional decline in Alzheimer’s disease (AD) is typically measured using single-time po...
Background: The prevalence of dementia is expected to rapidly increase in the next decades, warranti...
The widespread use of smartphones and sensors has made physiology, environment, and public health no...
Cognitive impairment due to dementia decreases functionality in Activities of Daily Living (ADL). It...
Dementia is the most widespread neurodegenerative disorder globally, and is associated with an immen...
The prevalence of dementia is increasing and poses a health challenge for individuals and society. D...
Alzheimer’s disease (AD) and other neurodegenerative diseases such as Parkinson’s disease (PD) and H...
Background: Mobile and wearable technology presents exciting opportunities for monitoring behavior u...
International audienceAlzheimer disease (AD) and other related dementia represent a major challenge ...
\ua9 2022 the Alzheimer\u27s Association. BACKGROUND: The Early Detection of Neurodegeneration (EDoN...
This is the final version of the article. Available from BioMed Central via the DOI in this record.T...
Frontotemporal dementia (FTD) is a heterogenous neurodegenerative disease and is caused by an autoso...
BackgroundThe majority of people with dementia prefer to live independently and safely in their own ...
Background: Functional decline in Alzheimer’s disease (AD) is typically measured using single-time p...
People living with cognitive impairment and dementia require regular screening of their symptomatolo...
Background Functional decline in Alzheimer’s disease (AD) is typically measured using single-time po...
Background: The prevalence of dementia is expected to rapidly increase in the next decades, warranti...
The widespread use of smartphones and sensors has made physiology, environment, and public health no...
Cognitive impairment due to dementia decreases functionality in Activities of Daily Living (ADL). It...
Dementia is the most widespread neurodegenerative disorder globally, and is associated with an immen...
The prevalence of dementia is increasing and poses a health challenge for individuals and society. D...
Alzheimer’s disease (AD) and other neurodegenerative diseases such as Parkinson’s disease (PD) and H...
Background: Mobile and wearable technology presents exciting opportunities for monitoring behavior u...
International audienceAlzheimer disease (AD) and other related dementia represent a major challenge ...
\ua9 2022 the Alzheimer\u27s Association. BACKGROUND: The Early Detection of Neurodegeneration (EDoN...
This is the final version of the article. Available from BioMed Central via the DOI in this record.T...
Frontotemporal dementia (FTD) is a heterogenous neurodegenerative disease and is caused by an autoso...
BackgroundThe majority of people with dementia prefer to live independently and safely in their own ...
Background: Functional decline in Alzheimer’s disease (AD) is typically measured using single-time p...
People living with cognitive impairment and dementia require regular screening of their symptomatolo...
Background Functional decline in Alzheimer’s disease (AD) is typically measured using single-time po...